Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 126

Similar articles for PubMed (Select 24146352)

1.

Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group.

Svicher V, Alteri C, Montano M, Nori A, D'Arrigo R, Andreoni M, Angarano G, Antinori A, Antonelli G, Allice T, Bagnarelli P, Baldanti F, Bertoli A, Borderi M, Boeri E, Bon I, Bruzzone B, Barresi R, Calderisi S, Callegaro AP, Capobianchi MR, Gargiulo F, Castelli F, Cauda R, Ceccherini-Silberstein F, Clementi M, Chirianni A, Colafigli M, D'Arminio Monforte A, De Luca A, Di Biagio A, Di Nicuolo G, Di Perri G, Di Santo F, Fadda G, Galli M, Gennari W, Ghisetti V, Costantini A, Gori A, Gulminetti R, Leoncini F, Maffongelli G, Maggiolo F, Maserati R, Mazzotta F, Meini G, Micheli V, Monno L, Mussini C, Nozza S, Paolucci S, Palù G, Parisi S, Parruti G, Pignataro AR, Quirino T, Re MC, Rizzardini G, Sanguinetti M, Santangelo R, Scaggiante R, Sterrantino G, Turriziani O, Vatteroni ML, Viscoli C, Vullo V, Zazzi M, Lazzarin A, Perno CF.

Infection. 2014 Feb;42(1):61-71. doi: 10.1007/s15010-013-0510-3. Epub 2013 Oct 22.

2.

High concordance of genotypic coreceptor prediction in plasma-viral RNA and proviral DNA of HIV-1 subtype C: implications for use of whole blood DNA in resource-limited settings.

Gupta S, Neogi U, Srinivasa H, Shet A.

J Antimicrob Chemother. 2013 Sep;68(9):2003-6. doi: 10.1093/jac/dkt138. Epub 2013 Apr 30.

3.

Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group.

Svicher V, Alteri C, Montano M, D'Arrigo R, Andreoni M, Angarano G, Antinori A, Antonelli G, Allice T, Bagnarelli P, Baldanti F, Bertoli A, Borderi M, Boeri E, Bon I, Bruzzone B, Callegaro AP, Capobianchi MR, Carosi G, Cauda R, Ceccherini-Silberstein F, Clementi M, Chirianni A, Colafigli M, D'Arminio Monforte A, De Luca A, Di Biagio A, Di Nicuolo G, Di Perri G, Di Pietro M, Di Santo F, Fabeni L, Fadda G, Galli M, Gennari W, Ghisetti V, Giacometti A, Gori C, Gori A, Gulminetti R, Leoncini F, Maffongelli G, Maggiolo F, Manca G, Gargiulo F, Martinelli C, Maserati R, Mazzotta F, Meini G, Micheli V, Monno L, Mussini C, Narciso P, Nozza S, Paolucci S, Pal G, Parisi S, Parruti G, Pignataro AR, Pollicita M, Quirino T, Re MC, Rizzardini G, Santangelo R, Scaggiante R, Sterrantino G, Turriziani O, Vatteroni ML, Vecchi L, Viscoli C, Vullo V, Zazzi M, Lazzarini A, Perno CF; DIVA group.

New Microbiol. 2012 Jan;35(1):17-25. Epub 2012 Jan 10.

4.

High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists.

Seclén E, Garrido C, González Mdel M, González-Lahoz J, de Mendoza C, Soriano V, Poveda E.

J Antimicrob Chemother. 2010 Jul;65(7):1486-92. doi: 10.1093/jac/dkq137. Epub 2010 Apr 28.

5.

Impact of triplicate testing on HIV genotypic tropism prediction in routine clinical practice.

Symons J, Vandekerckhove L, Paredes R, Verhofstede C, Bellido R, Demecheleer E, van Ham PM, van Lelyveld SF, Stam AJ, van Versendaal D, Nijhuis M, Wensing AM.

Clin Microbiol Infect. 2012 Jun;18(6):606-12. doi: 10.1111/j.1469-0691.2011.03631.x. Epub 2011 Sep 9.

6.

Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy.

Meini G, Rossetti B, Bianco C, Ceccherini-Silberstein F, Di Giambenedetto S, Sighinolfi L, Monno L, Castagna A, Rozera G, D'Arminio Monforte A, Zazzi M, De Luca A; ICONA Foundation Group.

J Antimicrob Chemother. 2014 Mar;69(3):735-41. doi: 10.1093/jac/dkt426. Epub 2013 Oct 23.

7.

Results of external quality assessment for proviral DNA testing of HIV tropism in the Maraviroc Switch collaborative study.

Tu E, Swenson LC, Land S, Pett S, Emery S, Marks K, Kelleher AD, Kaye S, Kaiser R, Schuelter E, Harrigan R; MARCH Laboratory Group and the MARCH Study Group.

J Clin Microbiol. 2013 Jul;51(7):2063-71. doi: 10.1128/JCM.00510-13. Epub 2013 Apr 17.

8.

HIV-1 coreceptor usage in paired plasma RNA and proviral DNA from patients with acute and chronic infection never treated with antiretroviral therapy.

Bon I, Turriziani O, Musumeci G, Clò A, Montagna C, Morini S, Calza L, Gibellini D, Antonelli G, Re MC.

J Med Virol. 2015 Feb;87(2):315-22. doi: 10.1002/jmv.24036. Epub 2014 Aug 20.

PMID:
25138591
9.

Prediction of HIV-1 coreceptor usage (tropism) by sequence analysis using a genotypic approach.

Sierra S, Kaiser R, Lübke N, Thielen A, Schuelter E, Heger E, Däumer M, Reuter S, Esser S, Fätkenheuer G, Pfister H, Oette M, Lengauer T.

J Vis Exp. 2011 Dec 1;(58). pii: 3264. doi: 10.3791/3264.

10.

Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping.

Prosperi MC, Bracciale L, Fabbiani M, Di Giambenedetto S, Razzolini F, Meini G, Colafigli M, Marzocchetti A, Cauda R, Zazzi M, De Luca A.

Retrovirology. 2010 Jun 30;7:56. doi: 10.1186/1742-4690-7-56.

11.

Stability of unfrozen whole blood DNA for remote genotypic analysis of HIV-1 coreceptor tropism.

Meini G, Materazzi A, Saladini F, Rosi A, Vicenti I, Mancini M, Pirazzoli A, Caudai C, Zazzi M.

BMC Infect Dis. 2013 Oct 30;13:508. doi: 10.1186/1471-2334-13-508.

12.

HIV-1 tropism: a comparison between RNA and proviral DNA in routine clinical samples from Chilean patients.

Ferrer P, Montecinos L, Tello M, Tordecilla R, Rodríguez C, Ferrés M, Pérez CM, Beltrán C, Guzmán MA, Afani A.

Virol J. 2013 Oct 28;10:318. doi: 10.1186/1743-422X-10-318.

13.

Evaluation of genotypic tropism prediction tests compared with in vitro co-receptor usage in HIV-1 primary isolates of diverse subtypes.

Delgado E, Fernández-García A, Vega Y, Cuevas T, Pinilla M, García V, Sánchez M, González M, Sánchez AM, Thomson MM, Pérez-Álvarez L.

J Antimicrob Chemother. 2012 Jan;67(1):25-31. doi: 10.1093/jac/dkr438. Epub 2011 Oct 18.

14.

Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonists.

Soulié C, Fourati S, Lambert-Niclot S, Malet I, Wirden M, Tubiana R, Valantin MA, Katlama C, Calvez V, Marcelin AG.

J Antimicrob Chemother. 2010 Apr;65(4):749-51. doi: 10.1093/jac/dkq029. Epub 2010 Feb 11.

15.

Evolution of proviral DNA HIV-1 tropism under selective pressure of maraviroc-based therapy.

Baroncelli S, Galluzzo CM, Weimer LE, Pirillo MF, Volpe A, Mercuri A, Cavalli A, Fragola V, Monno L, Degli Antoni A, Ladisa N, Francisci D, Bucciardini R, Floridia M.

J Antimicrob Chemother. 2012 Jun;67(6):1479-85. doi: 10.1093/jac/dks055. Epub 2012 Feb 23.

16.

Concordance between HIV-1 genotypic coreceptor tropism predictions based on plasma RNA and proviral DNA.

Verhofstede C, Brudney D, Reynaerts J, Vaira D, Fransen K, De Bel A, Seguin-Devaux C, De Wit S, Vandekerckhove L, Geretti AM.

HIV Med. 2011 Oct;12(9):544-52. doi: 10.1111/j.1468-1293.2011.00922.x. Epub 2011 Apr 25.

PMID:
21518222
17.

Selected amino acid mutations in HIV-1 B subtype gp41 are associated with specific gp120v₃ signatures in the regulation of co-receptor usage.

Dimonte S, Mercurio F, Svicher V, D'Arrigo R, Perno CF, Ceccherini-Silberstein F.

Retrovirology. 2011 May 12;8:33. doi: 10.1186/1742-4690-8-33.

18.

Improved detection of CXCR4-using HIV by V3 genotyping: application of population-based and "deep" sequencing to plasma RNA and proviral DNA.

Swenson LC, Moores A, Low AJ, Thielen A, Dong W, Woods C, Jensen MA, Wynhoven B, Chan D, Glascock C, Harrigan PR.

J Acquir Immune Defic Syndr. 2010 Aug;54(5):506-10. doi: 10.1097/QAI.0b013e3181d0558f.

PMID:
20512044
19.

A genotypic HIV-1 proviral DNA coreceptor tropism assay: characterization in viremic subjects.

Brown J, Burger H, Weiser B, Pollard RB, Li XD, Clancy LJ, Baumann RE, Rogers AA, Hamdan HB, Pesano RL, Kagan RM.

AIDS Res Ther. 2014 May 21;11:14. doi: 10.1186/1742-6405-11-14. eCollection 2014.

20.

Maraviroc treatment in non-R5-HIV-1-infected patients results in the selection of extreme CXCR4-using variants with limited effect on the total viral setpoint.

McGovern RA, Symons J, Poon AF, Harrigan PR, van Lelyveld SF, Hoepelman AI, van Ham PM, Dong W, Wensing AM, Nijhuis M.

J Antimicrob Chemother. 2013 Sep;68(9):2007-14. doi: 10.1093/jac/dkt153. Epub 2013 May 14.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk